Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...

US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...

Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...

Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...

A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy. Olema will hold a conference call to discuss these ...

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports.

Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ...